Download PDF
Dtsch Med Wochenschr 2003; 128(31/32): 1665-1669
DOI: 10.1055/s-2003-41098
Fachgremien & Konsensuskonferenzen
© Georg Thieme Verlag Stuttgart · New York

Indikationen für den Einsatz von Immunglobulinen

Ergebnisse einer Konsensuskonferenz an der Medizinischen Hochschule HannoverIndications for the use of immunoglobulin therapyH. Heiken1 , R. E. Schmidt1
  • 1Abteilung Klinische Immunologie (Direktor: Prof. Dr. R. E. Schmidt) Medizinische Hochschule Hannover
Further Information

Publication History

eingereicht: 31.3.2003

akzeptiert: 2.6.2003

Publication Date:
01 August 2003 (online)

Also available at
    Permissions and Reprints

Fortschritte in der Medizin, aber auch zunehmende ökonomische Überlegungen, machen eine regelmäßige Diskussion der Indikationen für Immunglobuline erforderlich. In den letzten Jahren ist es zu einem Mangel an Immunglobulinpräparaten gekommen, unter anderem bedingt durch den vermehrten Einsatz von Immunglobulinen in den Vereinigten Staaten von Amerika sowie durch vermehrte zulassungsüberschreitende Anwendung (sog. „Off-Label-Use”) insbesondere in der Neurologie. Zudem hat das Bundessozialgericht in Kassel am 19.03.2002 ein Urteil zur Kostenerstattung für „Off-Label”-Verordnungen gefällt, das auch, aber nicht nur, für den Einsatz der kostenintensiven Immunglobulintherapie von Bedeutung ist. Nach diesem Urteil müssen für den Einsatz eines Präparates außerhalb der zugelassenen Anwendungsgebiete streng definierte Bedingungen erfüllt sein (siehe Anhang). Am 28.10.2002 fand an der Medizinischen Hochschule Hannover eine Konsensuskonferenz zum Einsatz von Immunglobulinen statt. Nachfolgend werden die wichtigsten Ergebnisse dieser Konferenz zur Immunglobulintherapie vorgestellt.

Literatur

  • 1 The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group . Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.  N Engl J Med. 1991;  325 73-80
    Google Scholar
  • 2 The American Society of Hematology ITP Practice Guideline Panel . Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology.  Ann Intern Med. 1997;  126 319-326
    Google Scholar
  • 3 Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group . Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome.  Lancet. 1997;  349 225-230
    Google Scholar
  • 4 Achiron A, Gabbay U, Gilad R. et al . Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.  Neurology. 1998;  50 398-402
    Google Scholar
  • 5 Alejandria M M, Lansang M A, Dans L F, Mantaring J B. Intravenous immunoglobulin for treating sepsis and septic shock.  Cochrane Database Syst Rev. 2002;  CD001090
    Google Scholar
  • 6 Azulay J P, Blin O, Pouget J. et al . Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.  Neurology. 1994;  44 429-432
    Google Scholar
  • 7 Barron K S, Murphy D J, Silverman E D. et al . Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin.  J Pediatr. 1990;  117 638-644
    Google Scholar
  • 8 Blanchette V, Imbach P, Andrew M. et al . Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.  Lancet. 1994;  344 703-707
    Google Scholar
  • 9 Blanchette V S, Luke B, Andrew M. et al . A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.  J Pediatr. 1993;  123 989-995
    Google Scholar
  • 10 Bril V, Ilse W K, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome.  Neurology. 1996;  46 100-103
    Google Scholar
  • 11 Busse P J, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.  J Allergy Clin Immunol. 2002;  109 1001-1004
    Google Scholar
  • 12 Dalakas M C, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome.  N Engl J Med. 2001;  345 1870-1876
    Google Scholar
  • 13 Dalakas M C, Illa I, Dambrosia J M. et al . A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.  N Engl J Med. 1993;  329 1993-2000
    Google Scholar
  • 14 Dalakas M C, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.  Neurology. 2001;  56 323-327
    Google Scholar
  • 15 Dybul M, Fauci A S, Bartlett J G, Kaplan J E, Pau A K. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.  Ann Intern Med. 2002;  137 381-433
    Google Scholar
  • 16 Dyck P J, Litchy W J, Kratz K M. et al . A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 1994;  36 838-845
    Google Scholar
  • 17 Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Austrian Immunoglobulin in Multiple Sclerosis Study Group . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis.  Lancet. 1997;  349 589-593
    Google Scholar
  • 18 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.  Neurology. 2000;  55 1256-1262
    Google Scholar
  • 19 Feinstein L C, Seidel K, Jocum J. et al . Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.  Biol Blood Marrow Transplant. 1999;  5 369-378
    Google Scholar
  • 20 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group . Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.  Ann Neurol. 1997;  41 789-796
    Google Scholar
  • 21 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.  Brain. 1996;  119 1067-1077
    Google Scholar
  • 22 Howard J F. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis.  Neurology. 1998;  51 S30-S36
    Google Scholar
  • 23 Hundt M, Manger K, Dorner T. et al . Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin.  Rheumatology (Oxford). 2000;  39 1301-1302
    Google Scholar
  • 24 Kumar R, Ghali A, Ekaldious A W, Mahmoud O I, Al L umai AS. Post-transfusion purpura: case report.  Ann Hematol. 2001;  80 488-491
    Google Scholar
  • 25 Laupland K B, Dele D H. Epidemiology, etiology, and management of Kawasaki disease: state of the art.  Pediatr Cardiol. 1999;  20 177-183
    Google Scholar
  • 26 Lederman H M, Winkelstein J A. X-linked agammaglobulinemia: an analysis of 96 patients.  Medicine (Baltimore). 1985;  64 145-156
    Google Scholar
  • 27 Leger J M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.  Brain. 2001;  124 145-153
    Google Scholar
  • 28 Levy J, Espanol-Boren T, Thomas C. et al . Clinical spectrum of X-linked hyper-IgM syndrome.  J Pediatr. 1997;  131 47-54
    Google Scholar
  • 29 Mendell J R, Barohn R J, Freimer M L. et al . Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.  Neurology. 2001;  56 445-449
    Google Scholar
  • 30 Mofenson L M, Moye J , Korelitz J, Bethel J, Hirschhorn R, Nugent R. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group . Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children.  Pediatr Infect Dis J. 1994;  13 477-484
    Google Scholar
  • 31 Newburger J W, Takahashi M, Burns J C. et al . The treatment of Kawasaki syndrome with intravenous gamma globulin.  N Engl J Med. 1986;  315 341-347
    Google Scholar
  • 32 Nydegger U E. Sepsis and polyspecific intravenous immunoglobulins.  J Clin Apheresis. 1997;  12 93-99
    Google Scholar
  • 33 Prins C, Kerdel F A, Padilla R S. et al . Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.  Arch Dermatol. 2003;  139 26-32
    Google Scholar
  • 34 Report of an IUIS Scientific Committee . Primary Immunodeficiency Diseases.  Clin Exp Immunol. 1999;  118 1-28
    Google Scholar
  • 35 Schmidt R E, Budde U, Schafer G, Stroehmann I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura.  Lancet. 1981;  2 475-476
    Google Scholar
  • 36 Sicherer S H, Winkelstein J A. Primary immunodeficiency diseases in adults.  JAMA. 1998;  279 58-61
    Google Scholar
  • 37 Sorensen P S, Wanscher B, Jensen C V. et al . Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.  Neurology. 1998;  50 1273-1281
    Google Scholar
  • 38 Stangel M, Hartung H P. Intravenous immunoglobulins in multiple sclerosis. Studies and mechanisms of action - an update.  Nervenarzt. 2002;  73 119-124
    Google Scholar
  • 39 Sullivan K M, Storek J, Kopecky K J. et al . A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.  Biol Blood Marrow Transplant. 1996;  2 44-53
    Google Scholar
  • 40 Sultan Y, Kazatchkine M D, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors.  Am J Med. 1991;  91 35S-39S
    Google Scholar
  • 41 Uchino H, Yasunaga K, Akatsuka J. A cooperative clinical trial of high-dose immunoglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura.  Thromb Haemost. 1984;  51 182-185
    Google Scholar
  • 42 Van den Berg L H, Kerkhoff H, Oey P L. et al . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  59 248-252
    Google Scholar
  • 43 van der Meche F G, Schmitz P I. Dutch Guillain-Barre Study Group . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome.  N Engl J Med. 1992;  326 1123-1129
    Google Scholar
  • 44 van Doorn P A, Brand A, Strengers P F, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.  Neurology. 1990;  40 209-212
    Google Scholar
  • 45 Viard I, Wehrli P, Bullani R. et al . Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.  Science. 1998;  282 490-493
    Google Scholar
  • 46 Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis.  Curr Opin Crit Care. 2001;  7 354-361
    Google Scholar
  • 47 Winston D J, Antin J H, Wolff S N. et al . A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.  Bone Marrow Transplant. 2001;  28 187-196
    Google Scholar

Dr. med. Hans Heiken
Prof. Dr. med. Reinhold E. Schmidt

Abteilung Klinische Immunologie, Medizinische Hochschule Hannover

Carl-Neuberg-Straße 1

30625 Hannover

Email: Heiken.Hans@MH-Hannover.de

Email: Immunologie@MH-Hannover.de

      >